A Phase 3 Open-label Study to Evaluate the Safety of MEDI3250 in Healthy Japanese Children Age 2 Years Through 6 Years

Trial Profile

A Phase 3 Open-label Study to Evaluate the Safety of MEDI3250 in Healthy Japanese Children Age 2 Years Through 6 Years

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Oct 2015

At a glance

  • Drugs MEDI 3250 (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions; Registrational
  • Sponsors AstraZeneca
  • Most Recent Events

    • 02 Sep 2015 According to a Daiichi Sankyo media release, data from this will support regulatory submission in Japan.
    • 09 Mar 2015 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
    • 22 Dec 2014 Planned End Date changed from 1 May 2015 to 1 Mar 2015, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top